Jones Day

Antitrust; Competition Law; Banking Law; Finance; Business Restructuring; Reorganization; Capital Markets; Corporate Criminal Investigations; Employee Benefits; Executive Compensation; Energy; Environmental Law; Health Law; Safety; Financial Institutions Litigation; Regulation; Government Regulation; Insurance Recovery; Health Care; Intellectual Property; International Litigation; Arbitration; Issues; Appellate Practice; Labor and Employment; Mergers and Acquisitions; Private Equity; Product Liability; Torts; Real Estate; Securities; Shareholder Litigation; Sec Enforcement; Tax Law; Trial Practice.

"Universal Rule": Trademark Licenses Not Assignable in Bankruptcy Absent Express Authorization
Joseph M. Tiller, December 9, 2011
Two fundamental goals of chapter 11 of the Bankruptcy Code are rehabilitating a debtor's business and maximizing the value of the debtor's estate for the benefit of various stakeholders. In serving these goals, section 365(a) of the Bankruptcy Code allows a bankruptcy trustee or chapter 11 debtor...

TARP and SBLF Repayments by Bank Holding Companies
Brett P. Barragate,Bradley C. Brasser,Owen T. Conroy,Ralph F. MacDonald,Lawrence K. Nesbitt,James C. Olson,Heith D. Rodman, December 9, 2011
The Treasury invested $204.9 billion in 707 banking organizations pursuant to the Troubled Asset Relief Program ("TARP") Capital Purchase Program ("CPP"). Most larger banks have repaid TARP. More recently, 137 recipients with less than $10 billion of assets repaid TARP CPP...

Do Compounding Pharmacies "Live in Sin"? The FDA's Assertion of Enforcement Authority Over Pharmacy Compounding, and Two Courts' Efforts to Bless the Practice
Jonathan Berman,Michael Sennett, November 7, 2011
Pharmacy compounding, as the Food and Drug Administration (“FDA”) explains, “is an age-old practice in which pharmacists combine ¿ ingredients to create unique medications that meet specific needs of individual patients.” The FDA has recognized that “pharmacy...

Return to the Jones Day Firm Overview